Tolerability, pharmacokinetics and pharmacodynamics of multiple-ascending doses of GLPG 0634 in volunteers

Trial Profile

Tolerability, pharmacokinetics and pharmacodynamics of multiple-ascending doses of GLPG 0634 in volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Dec 2013

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 20 Dec 2013 New trial record
    • 30 Oct 2013 Results assessing pharmacodynamic outcomes for GLPG 0634 and a major metabolite presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top